84
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Childhood Cerebral Adrenoleukodystrophy: Case Report and Literature Review Advocating for Newborn Screening

ORCID Icon, ORCID Icon, &
Pages 75-83 | Received 16 Feb 2024, Accepted 12 Jun 2024, Published online: 17 Jun 2024

References

  • Kemp S, Berger J, Aubourg P. X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta Mol Basis Dis. 2012;1822(9):1465–1474. doi:10.1016/j.bbadis.2012.03.012
  • Engelen M, Barbier M, Dijkstra IME, et al. X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain. 2014;137(3):693–706. doi:10.1093/brain/awt361
  • Raymond GV, Moser AB, Fatemi A. X-Linked Adrenoleukodystrophy. Seattle: University of Washington; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1315/. Accessed June 13, 2024.
  • Sevin C, Hatteb S, Clément A, et al. Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden of disease - A population-based study. Orphanet J Rare Dis. 2023;18(1). doi:10.1186/s13023-023-02843-x
  • Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison’s disease in young adult male patients. J Clin Endocrinol Metab. 1996;81(2):470–474. doi:10.1210/jcem.81.2.8636252
  • Traboulsi EI, Maumenee IH. Ophthalmologic manifestations of X-linked childhood adrenoleulcodystrophy. Ophthalmology. 1987;94(1):47–52. doi:10.1016/s0161-6420(87)33504-3
  • Albersen M, van der Beek SL, Dijkstra IME, et al. Sex‐specific newborn screening for X‐linked adrenoleukodystrophy. J Inherit Metab Dis. 2023;46(1):116–128. doi:10.1002/jimd.12571
  • Vogel BH, Bradley SE, Adams DJ, et al. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol Genet Metab. 2015;114(4):599–603. doi:10.1016/j.ymgme.2015.02.002
  • Chen H-A, Hsu R-H, Chen P-W, et al. High incidence of null variants identified from newborn screening of X-linked adrenoleukodystrophy in Taiwan. Mol Genet Metab Rep. 2022;32(100902):100902. doi:10.1016/j.ymgmr.2022.100902
  • Natarajan A, Christopher R, Palakuzhiyil SV, Chandra SR. Utility of measuring very long-chain fatty-acyl carnitines in dried blood spots for newborn screening of X-linked Adrenoleukodystrophy. Mol Genet Metab Rep. 2021;26(100720):100720. doi:10.1016/j.ymgmr.2021.100720
  • Leukodystrophy. National Institute of Neurological Disorders and Stroke; 2023. Available from: https://www.ninds.nih.gov/health-information/disorders/leukodystrophy. Accessed June 13, 2024.
  • Moser A, Jones R, Hubbard W, et al. Newborn screening for X-linked adrenoleukodystrophy. Int J Neonatal Screen. 2016;2(4):15. doi:10.3390/ijns2040015
  • Khan M, Singh J, Gilg AG, Uto T, Singh I. Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy. J Lipid Res. 2010;51(7):1685–1695. doi:10.1194/jlr.m002329
  • Turk BR, Theda C, Fatemi A, Moser AB. X‐linked adrenoleukodystrophy: pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020;80(1):52–72. doi:10.1002/jdn.10003
  • Kanakis G, Kaltsas G. Adrenal Insufficiency Due to X-Linked Adrenoleukodystrophy. MDText.com; 2018.
  • Powers JM, Schaumburg HH. Adreno-leukodystrophy (sex-linked schilder’s disease): a pathogenetic hypothesis based on ultrastructural lesions in adrenal cortex, peripheral nerve and testis. Am J Pathol. 1974;76(3):481.
  • Kennedy CR, Allen JT, Fensom AH, Steinberg SJ, Wilson R. X-linked adrenoleukodystrophy with non-diagnostic plasma very long chain fatty acids. J Neurol Neurosurg Psychiatry. 1994;57(6):759–761. doi:10.1136/jnnp.57.6.759
  • Semmler A, Bao X, Cao G, et al. Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample. J Neurol. 2009;256(8):1277–1280. doi:10.1007/s00415-009-5114-6
  • Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7(1):51. doi:10.1186/1750-1172-7-51
  • Diagnosis of ALD. Adrenoleukodystrophy.info; 2023. Available from: https://adrenoleukodystrophy.info/clinical-diagnosis/diagnosis-of-ald. Accessed June 13, 2024.
  • Cartier N, Hacein-Bey-Abina S, Bartholomae CC, et al. Lentiviral hematopoietic cell gene therapy for X-linked adrenoleukodystrophy. In: Methods in Enzymology. Elsevier; 2012:187–198.
  • Gupta AO, Raymond G, Pierpont EI, et al. Treatment of cerebral adrenoleukodystrophy: allogeneic transplantation and lentiviral gene therapy. Expert Opin Biol Ther. 2022;22(9):1151–1162. doi:10.1080/14712598.2022.2124857
  • Prieto Tenreiro A, Penacho Lázaro MÁ, Andrés Celda R, Fernández Fernández M, González Mateo C, Díez Hernández A. Dietary treatment for X-linked adrenoleukodystrophy: is “Lorenzo’s oil” useful? Endocrinol Nutr. 2013;60(1):37–39. doi:10.1016/j.endoen.2012.01.008